Compare TRS & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRS | ODTX |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2004 | 2025 |
| Metric | TRS | ODTX |
|---|---|---|
| Price | $38.42 | $24.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $41.50 | N/A |
| AVG Volume (30 Days) | ★ 290.7K | 218.6K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 21.96 | N/A |
| Revenue | ★ $645,720,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $4.27 | N/A |
| P/E Ratio | $1.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.43 | $15.10 |
| 52 Week High | $45.43 | $29.05 |
| Indicator | TRS | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 50.72 |
| Support Level | $38.24 | $21.48 |
| Resistance Level | $39.33 | $28.53 |
| Average True Range (ATR) | 0.80 | 2.23 |
| MACD | -0.00 | -0.40 |
| Stochastic Oscillator | 28.71 | 29.47 |
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.